ecrin-mdr-crcClinical2009Colorectal CancerColorectal NeoplasmsColorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2058515United States11bPrior therapyMetastatic cancerCetuximabECRIN MDRTerminatedfalseStudy of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal CancerOpen-label phase 1b trial. Study treatment will be administered in 3 week cycles. There are two distinct parts in this study: * Part 1: Dose escalation from IMO-2055 * Part 2: Once a recommended phase 2 dose is found additional tolerability and pharmacodynamics will be explored2009-01-152058515NCT00719199